p73, a protein that has substantial structural and functional similarity to p53, has recently been identi®ed. It was found to be monoallelically expressed in all cell lines and normal individuals tested. To elucidate its role in cancer development and as a potential imprinted tumor suppressor, we investigated the allele-speci®c expression of the human p73 gene in 28 cases of renal cell carcinoma and its imprinting status in fetal pancreatic and thymic tissues. Of 12 informative pairs of renal cell carcinoma and matched normal tissues identi®ed by StyI restriction fragment length polymorphism (RFLP) in exon 2, p73 showed monoallelic expression in 11 out of 12 normal tissues but biallelic expression in 8/12 and switched allele expression in 2/12 of the matched corresponding cancers. An imprinting study of the p73 gene in two families using a newly identi®ed exonic BanI RFLP indicated that expression of p73 was limited to the maternal allele in RNA from fetal pancreas and thymus, demonstrating that p73 is imprinted in at least these two tissues. These ®ndings strongly suggest that loss of imprinting or switching of allelic expression of the p73 gene is associated with the development of renal cell carcinoma.
Keywords: p73; imprinting; allelic expression; renal cell carcinoma p73 is considered as an imprinted tumor suppressor gene based on numerous observations. First, p73 has substantial structural similarity to p53 in all three domains, (Kaghad et al., 1997 ; reviewed by Dickman, 1997) and functionally it induces programmed cell death by activating p21 Wa¯/Cipl (Jost et al., 1997) . Second, p73 maps to 1p36.33, a region which showed frequent deletions from the maternal chromosome in neuroblastoma and other tumors (Takeda et al., 1994; Versteeg et al., 1995) . Finally, monoallelic expression of p73 is present exclusively in numerous cell lines and normal tissues and individuals tested, as expected of an imprinted gene (Kaghad et al., 1997 ; reviewed by Oren, 1997) . However, no study to date has shown that p73 is imprinted by analysing its expression in human tissues isolated from suitably informative families.
We ®rst studied allele-speci®c expression of p73 in 28 pairs of clear cell renal carcinoma and matched normal renal tissues. Twelve heterozygous individuals were identi®ed by genomic PCR ampli®cation using primers located in introns 1 and 2, followed by StyI digestion (Figure 1a) . Allele-speci®c expression of p73 in the paired cancer and normal samples from these individuals was then performed by RT ± PCR using cDNA primers¯anking the C/T polymorphism and StyI restriction fragment length polymorphism (RFLP) (Figure 1b) . Monoallelic expression was identi®ed in the normal renal tissues of 11/12 of the informative individuals. In the corresponding 11 cancer samples that showed monoallelic expression of p73, we found that both alleles were expressed in seven (64%). Interestingly, in two cases (cases no. 1 and 9), the matched normal tissue only expressed the G/C alleles, while the corresponding cancer exclusively expressed the A/T alleles. The frequency of such switched allele expression in renal cell carcinoma is 17% (2/12). In three other cases, both cancer and matched normal renal tissues showed the same expression pattern; either both expressed two alleles (1/12) or both only expressed A/T alleles (2/12). These ®ndings are summarized in Table 1 , indicating that monoallelic expression of p73 is limited in normal renal tissue, while biallelic expression is evident in renal carcinoma. Biallelic expression of p73 could thus be an important step in tumorigenesis in the kidney. Switching of an imprinted gene from monoallelic expression in normal tissue to biallelic expression in cancer is called loss of imprinting (LOI) (Rainier et al., 1993) . To determine if the biallelic expression of p73 in renal cell carcinoma was due to LOI, we investigated the imprinting status of the p73 gene. Using a new polymorphism identi®ed in exon 5, a BanI RFLP due to a T to C change at nucleotide 629 of p73 (Nucleotide position is based on the cDNA sequence in the EMBL database under the accession number Y11416 EMBL), we screened DNA isolated from 48 families (Figure 2a) . We identi®ed two informative families that also had available fetal pancreatic or/and thymic tissue. The parental origin of the two alleles of p73 in the informative individuals was then determined by analysing their maternal genotypes (Figure 2b ). The parental origin of these informative cases from the fetal tissues was then determined. RNA was extracted from the same tissues and mother's blood. RT ± PCR was performed using cDNA primers¯anking the exon 5 polymorphism followed by BanI digestion. All three samples, corresponding to one fetal thymus and two fetal pancreas showed maternal allele expression of the p73 gene (Figure 2b ). These results suggest that the monoallelically expressed p73 is a maternal imprinting gene in fetal thymus and pancreas. Moreover, Kaghad et al. (1997) analysed one informative case and found that p73 was predominantly expressed from the maternal allele. Thus, we conclude that p73 is a maternal imprinting gene. Biallelic expression of the p73 gene, or LOI of p73, is involved in the development of renal cell carcinoma.
LOI was ®rst discovered during studies of IGF2 allelic expression in Wilms' tumor (Rainier et al., 1993) . Since then it has been described in several imprinted genes, including IGF2, HI9, IPW, and p57KIP2 (Ogawa et al., 1993; Hibi et al., 1996; Rachmilewitz et al., 1996; Thompson et al., 1996) . LOI involving IGF2 or/and H19 has been reported in about 14 dierent types of tumors (reviewed by McBride 1997; Oda et al., 1998) . The frequency of LOI involving dierent imprinting genes, in cancer ranges from 10 ± 70% (reviewed by Feinberg, 1993 ; reviewed by McBride, 1997) . In this paper, we found that p73 biallelically expressed in renal cell carcinoma and LOI of p73 in cancer in about 64% of cases. LOI of p73 in other cancers was even higher (data not shown). These data indicated that the LOI of p73 may be an early event in the development of renal cell carcinoma, as previously suggested that LOI of IGF2 occurred as an early event in tumorigenesis (McBride 1997) . This Table  1 respectively. The primers used for RT ± PCR analysis are p3 (5'-GGGCTGCGACGGCTGCAGAGC-3') and p4 (5'-GAGAG-CTCCAGAGGTGCTC-3') Tumor  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28   G2  G2  G1  G3  G2  G2  G2  G2  G3  G2  G2  G2  G1  G3  G2  G1  G2  G3  G2  G2  G2  G2  G1  G2  G2  G3  G4 (a) Schematic diagram of the exon 5 region of the p73 gene, indicating the location of the BanI polymorphic site and the primers used for genomic PCR (P5 and P6) and for RT ± PCR (P7 and P8). (b) Two informative families for BanI RFLP (bl and b2) were analysed for imprinting status of the p73 gene. The primers for genotyping of the two families are p5 (5'-CTGGACAGGGGTGCAGTTG-3') and p6 (5'-TGCTGTCGG-GATGCTG-3'). Std. represents fx174 RF DNA/HaeIII molecular marker (Gibco ± BRL). C1 and C2 are genomic controls for homozygous AT and GC alleles respectively. Both fetus in families b1 and b2 are heterozygous and have inherited the AT allele from their mother and the GC allele from their father. Expression analysis of the RNA isolated from fetal pancreas (RNAp) and thymus (RNAt) reveals only the AT allele indicating maternal imprinting of the p73 gene. The primers used for RT ± PCR analysis are p7 (5'-TTGAGGTCACTTTCCAG-CAG-3') and p8 (5'-TTGCCTTCCACGCGGATGAG-3') p73 expression in renal cel carcinoma M Mai et al hypothesis is supported by our detection of biallelic expression of p73 in high grade (grades 3 or 4) and low grade cases (Table 1) . The function and mechanism of LOI is still unclear, but LOI may result from epigenetic modi®cation of genomic sequence by methylation, acetylation, promoter usage, or changes in an imprinting center (reviewed by Tycko, 1997; Watanable and Barlow, 1996; Svensson et al., 1998) . The mechanism which resulted in LOI in p73 in renal cell carcinoma is unknown. Genomic analysis of the promoter or promoters of p73 and methylation analysis of the entire gene sequence may provide insights about the mechanism involved in LOI of p73 in renal cancer. Allelic switching expression of p73 in our two cases of renal cell carcinoma is rare and provocative. This phenomenon was only reported once in one individual involving the H19 gene in Wilms' tumor (Zhang et al., 1993) . DNA methylation probably plays an important role in the allele switching, but how can methylation alone repress the allele that is active in normal tissue and activate to express only the silent allele in cancer? One possibility is that there exists a methylation counter in cells which can detect the presence of a single methylated allele in an imprinting gene. In early tumorigenesis, the repressed allele is reactivated due to demethylation and starts being transcribed. However, the methylation counter is still functioning so as to methylate alternative allele to keep methylation balance in the cell. That causes allelic switching expression. Then at a certain point during early tumorigenesis, the function of methylation counter is disrupted. Both alleles of the imprinted gene escape from the methylation and start transcription resulting in LOI. Since the transition period between having methylation counter eect and losing methylation counter function might be very short, the allelic switching expression becomes very dicut to be detected when compared with LOI. This hypothesis remains to be investigated.
